Anti-Mouse CD22 (Clone MB22-11) - Biotin

Leinco Technologies
Product Code: LEI-C962
Product Group: Primary Antibodies
CodeSizePrice
LEI-C962-25ug25 ug£170.00
Quantity:
LEI-C962-100ug100 ug£211.00
Quantity:
LEI-C962-500ug500 ug£392.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Mouse IgG2c κ
Antibody Clonality: Monoclonal
Antibody Clone: MB22-11
Regulatory Status: RUO
Target Species: Mouse
Application: Functional Study
Shipping:
2 - 8°C Wet Ice
Storage:
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Further Information

Antigen Distribution:
CD22 is expressed by most mature B cell lineages.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Biotin
Format:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Mouse CD22 cDNA-transfected baby hamster kidney cells
Long Description:
Siglecs (sialic acid-binding immunoglobulin superfamily lectins) are a family of single pass, transmembrane cell surface proteins characterized by shared structural motifs and an ability to recognize sialic acids1, 2. CD22 (Siglec-2), a 140 kDa member of the Siglec family expressed by B cells3, 4, contains six C2-set domains, one V-set domain, and in its intracellular cytoplasmic tail has three immunoreceptor tyrosine-based inhibition motifs (ITIM) and one ITIM-like domain5. While murine Siglecs are not necessarily homologous to human Siglecs, CD22 is evolutionarily conserved and does have a direct human ortholog5. CD22 acts as an inhibitory B cell co-receptor that negatively regulates B cell activation, B reg cell expansion, and B cell receptor (BCR) signaling4. Upon ligation of BCR, ITIMs are phosphorylated, leading to recruitment and activation of SH2-containing phosphatases that then dephosphorylate signaling molecules activated by BCR ligation4. Additionally, CD22 regulates B cell response to inflammation and is a master regulator of microglial phagocytosis in the aging brain5. Evidence in mouse models suggests CD22 contributes to the pathogenesis of autoimmune diseases3. Loss of CD22 leads to hyperactivation of B cells5. CD22 mouse knockouts are defective in B cell development but do not develop lupus-like disease4. To generate MB22-11, CD22 knockout mice were immunized with mouse CD22 cDNA-transfected baby hamster kidney cells6. Spleen cells were fused with NS-1 myeloma cells, and hybridomas producing antibody specifically reactive with CD22-transfected mouse L cells were selected and purified. MB22-11 was isotyped as IgG2c due to its C57BL/6 origin; however, both IgG2a and IgG2c specific reagents have significant reactivity against MB22-11. In vitro, MB22-11 inhibits CD22-mediated adhesion by 90% and completely blocks CD22-Fc binding to T and B cells6. In vivo, MB22-11 significantly reduces peripheral blood, lymph node, and marginal zone B cell numbers6, 7. Additionally, in mice injected with MB22-11, blood, spleen, and lymph node B cell turnover is higher relative to injection with non-blocking monoclonal antibodies, and B cell surface expression of CD22 is reduced to nearly undetectable levels6.
NCBI Gene:
12483
Target:
CD22

References

1. Bochner BS. Clin Exp Allergy. 39(3):317-324. 2009. 2. Kiwamoto T, Kawasaki N, Paulson JC, et al. Pharmacol Ther. 135(3):327-336. 2012. 3. D?rner T, Shock A, Smith KG. Int Rev Immunol. 31(5):363-378. 2012. 4. Tsubata T. Immunol Med. 42(3):108-116. 2019. 5. Siddiqui SS, Matar R, Merheb M, et al. Cells. 8(10):1125. 2019. 6. Haas KM, Sen S, Sanford IG, et al. J Immunol. 177(5):3063-3073. 2006. 7. Haas KM, Watanabe R, Matsushita T, et al. J Immunol. 184(9):4789-4800. 2010.